Enveda Biosciences, a Boulder, CO-based biotech firm, raised $55M in Series B2 funding.

New investors Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy joined existing backers like Kinnevik, FPV, and True Ventures.

The funds will enhance Enveda's AI-powered drug discovery platform and support Phase I trials of its top three lead programs, including a promising novel oral anti-inflammatory agent for atopic dermatitis.

Founded by Viswa Colluru, Ph.D., Enveda leverages AI to identify, prioritize, and develop natural product-derived medicines. The company has raised a total of $230M to date.